Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer

Murray K., Oldfield L., Stefanova I., Gentiluomo M., Aretini P., O'Sullivan R., ...Daha Fazla

Seminars in Cancer Biology, cilt.111, ss.76-88, 2025 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 111
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1016/j.semcancer.2025.02.009
  • Dergi Adı: Seminars in Cancer Biology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, MEDLINE
  • Sayfa Sayıları: ss.76-88
  • Anahtar Kelimeler: Artificial intelligence, Biomarkers, Early detection, Omics, Pancreatic cancer
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, although urgently needed, remains elusive. Individuals in certain high-risk groups are, however, offered screening or surveillance. Here we explore advances in understanding high-risk groups for PDAC and efforts to implement biomarker-driven detection of PDAC in these groups. We review current approaches to early detection biomarker development and the use of artificial intelligence as applied to electronic health records (EHRs) and social media. Finally, we address the cost-effectiveness of applying biomarker strategies for early detection of PDAC.